Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics / Hsien Yuan Lane en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 353-358 Título : Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics Tipo de documento: texto impreso Autores: Hsien Yuan Lane, Autor ; Yue Cune Chang, Autor ; Chi Chiang Chiu, Autor Fecha de publicación: 2023 Artículo en la página: pp. 353-358 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Hospitalización, Pacientes, Risperidona, Esquizofrenia Resumen: Response predictors of risperidone or other newer atypical antipsychotics for schizophrenia treatment remain unclear. This study aimed to investigate the influence of patient demographics on risperidone efficacy for schizophrenia. One hundred twenty-one newly hospitalized patients who had schizophrenia with acute exacerbation entered this prospective, 6-week risperidone trial. Link: ./index.php?lvl=notice_display&id=31050 [artículo] Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics [texto impreso] / Hsien Yuan Lane, Autor ; Yue Cune Chang, Autor ; Chi Chiang Chiu, Autor . - 2023 . - pp. 353-358. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 353-358 Palabras clave: Antipsicóticos, Hospitalización, Pacientes, Risperidona, Esquizofrenia Resumen: Response predictors of risperidone or other newer atypical antipsychotics for schizophrenia treatment remain unclear. This study aimed to investigate the influence of patient demographics on risperidone efficacy for schizophrenia. One hundred twenty-one newly hospitalized patients who had schizophrenia with acute exacerbation entered this prospective, 6-week risperidone trial. Link: ./index.php?lvl=notice_display&id=31050

---

1 (1 - 1 / 1)